| 000 | 01399 a2200385 4500 | ||
|---|---|---|---|
| 005 | 20250516005843.0 | ||
| 264 | 0 | _c20110524 | |
| 008 | 201105s 0 0 eng d | ||
| 022 | _a1744-8409 | ||
| 024 | 7 |
_a10.1586/eci.10.57 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWirtz, Paul W | |
| 245 | 0 | 0 |
_a3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. _h[electronic resource] |
| 260 |
_bExpert review of clinical immunology _cNov 2010 |
||
| 300 |
_a867-74 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_a4-Aminopyridine _xadverse effects |
| 650 | 0 | 4 |
_aAction Potentials _xdrug effects |
| 650 | 0 | 4 | _aAmifampridine |
| 650 | 0 | 4 |
_aCalcium Channels _xmetabolism |
| 650 | 0 | 4 |
_aCholinergic Agents _xadverse effects |
| 650 | 0 | 4 | _aClinical Protocols |
| 650 | 0 | 4 |
_aEpilepsy _xetiology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLambert-Eaton Myasthenic Syndrome _xdrug therapy |
| 650 | 0 | 4 |
_aMuscles _xdrug effects |
| 650 | 0 | 4 |
_aParesthesia _xetiology |
| 650 | 0 | 4 |
_aPresynaptic Terminals _xdrug effects |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 700 | 1 | _aTitulaer, Maarten J | |
| 700 | 1 | _aGerven, Joop Ma van | |
| 700 | 1 | _aVerschuuren, Jan J | |
| 773 | 0 |
_tExpert review of clinical immunology _gvol. 6 _gno. 6 _gp. 867-74 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1586/eci.10.57 _zAvailable from publisher's website |
| 999 |
_c20280153 _d20280153 |
||